<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:media="http://search.yahoo.com/mrss/"><channel><title>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</title><description>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</description><link>https://www.neurologylive.com/news</link><category>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</category><copyright>© 2026 MJH Life Sciences™ and NeurologyLive - Clinical Neurology News and Neurology Expert Insights. All rights reserved.</copyright><lastBuildDate>Fri, 20 Nov 2026 23:22:31 +0000</lastBuildDate><ttl>5</ttl><atom:link href="https://www.neurologylive.com/rss.xml" rel="self" type="application/rss+xml"/><language>en-us</language><image><title>NeurologyLive - Clinical Neurology News and Neurology Expert Insights articles</title><width>144</width><height>47</height><link>https://www.neurologylive.com/news</link><url>https://www.neurologylive.com/logo.webp</url></image><item><title>&lt;![CDATA[NeurologyLive® Friday 5 — November 20, 2026]]&gt;</title><link>https://www.neurologylive.com/view/neurologylive-friday-5-november-20-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/neurologylive-friday-5-november-20-2026</guid><description>&lt;![CDATA[Take 5 minutes to catch up on NeurologyLive®&apos;s highlights from the week ending November 20, 2026. ]]&gt;</description><pubDate>Fri, 20 Nov 2026 20:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Rethinking Idiopathic Intracranial Hypertension as a Disorder of Arterial Hemodynamics]]&gt;</title><link>https://www.neurologylive.com/view/rethinking-idiopathic-intracranial-hypertension-as-disorder-arterial-hemodynamics</link><guid isPermaLink="true">https://www.neurologylive.com/view/rethinking-idiopathic-intracranial-hypertension-as-disorder-arterial-hemodynamics</guid><description>&lt;![CDATA[Chris Favilla, MD, stroke neurologist at the University of Pennsylvania, discusses findings that cerebral venous sinus stenting improves arterial hemodynamics in patients with idiopathic intracranial hypertension (IIH) and what they mean for understanding the disease.]]&gt;</description><pubDate>Fri, 20 Nov 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[5-Year Clarity AD Data Show Sustained Clinical Benefit With Lecanemab in Early Alzheimer Disease]]&gt;</title><link>https://www.neurologylive.com/view/5-year-clarity-ad-data-sustained-clinical-benefit-lecanemab-early-alzheimer-disease</link><guid isPermaLink="true">https://www.neurologylive.com/view/5-year-clarity-ad-data-sustained-clinical-benefit-lecanemab-early-alzheimer-disease</guid><description>&lt;![CDATA[5-year findings from the Clarity AD long-term extension, presented at CTAD 2026, showed progressively greater differences in CDR-SB outcomes compared with external natural history cohorts.]]&gt;</description><pubDate>Fri, 20 Nov 2026 18:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[When Does Barth Syndrome Get Worse? Stress &amp; the Disease Timeline]]&gt;</title><link>https://www.neurologylive.com/view/when-does-barth-syndrome-get-worse-stress-the-disease-timeline</link><guid isPermaLink="true">https://www.neurologylive.com/view/when-does-barth-syndrome-get-worse-stress-the-disease-timeline</guid><description>&lt;![CDATA[Dr. Vernon distinguishes Barth syndrome from other mitochondrial diseases: the cardiomyopathy-plus-neutropenia combination without neurologic involvement is unique.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[How to Diagnose Barth Syndrome in 2026]]&gt;</title><link>https://www.neurologylive.com/view/how-to-diagnose-barth-syndrome-in-2026</link><guid isPermaLink="true">https://www.neurologylive.com/view/how-to-diagnose-barth-syndrome-in-2026</guid><description>&lt;![CDATA[Dr. Vernon describes the evolution of genetic diagnosis -- from single-gene sequencing to whole exome/genome sequencing now achievable in 8 days for $3,000 -- compressing median time-to-diagnosis from years to months.]]&gt;</description><pubDate>Fri, 20 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Gray Areas: Has Traditional Immunotherapy Lost Its Place in Myasthenia Gravis?]]&gt;</title><link>https://www.neurologylive.com/view/gray-areas-has-traditional-immunotherapy-lost-its-place-myasthenia-gravis</link><guid isPermaLink="true">https://www.neurologylive.com/view/gray-areas-has-traditional-immunotherapy-lost-its-place-myasthenia-gravis</guid><description>&lt;![CDATA[At the 2026 AANEM Annual Meeting, Michael Hehir, MD, makes the case that traditional immunotherapy still belongs at the center of long-term myasthenia gravis management, citing outcome data, patient burden, and the costs that often go undiscussed.]]&gt;</description><pubDate>Fri, 20 Nov 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Brain Chat: Nerve-Racking Facial Pain and Rare Headaches]]&gt;</title><link>https://www.neurologylive.com/view/brain-chat-nerve-racking-facial-pain-rare-headaches</link><guid isPermaLink="true">https://www.neurologylive.com/view/brain-chat-nerve-racking-facial-pain-rare-headaches</guid><description>&lt;![CDATA[Mitzi Joi Williams, MD, is joined by Temitope Adeyey, MD, and Chantale Branson, MD, to discuss headache and facial pain conditions beyond migraine. ]]&gt;</description><pubDate>Fri, 20 Nov 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Gut Microbiome Emerging as a Modifiable Target in Stroke Risk and Recovery]]&gt;</title><link>https://www.neurologylive.com/view/gut-microbiome-emerging-modifiable-target-stroke-risk-and-recovery</link><guid isPermaLink="true">https://www.neurologylive.com/view/gut-microbiome-emerging-modifiable-target-stroke-risk-and-recovery</guid><description>&lt;![CDATA[William Roth, MD, assistant professor of neurology at the University of Chicago, discusses the role of the gut microbiome in stroke risk and recovery and emerging strategies to modify it in the acute and preventive settings.]]&gt;</description><pubDate>Thu, 19 Nov 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Pooled Review Finds No Benefit, More Bleeding With Distal Clot Removal]]&gt;</title><link>https://www.neurologylive.com/view/pooled-review-finds-no-benefit-more-bleeding-with-distal-clot-removal</link><guid isPermaLink="true">https://www.neurologylive.com/view/pooled-review-finds-no-benefit-more-bleeding-with-distal-clot-removal</guid><description>&lt;![CDATA[Three randomized trials pooled in a new systematic review found that thrombectomy did not improve 90-day functional outcomes after medium or distal vessel occlusion stroke, while increasing bleeding risk.]]&gt;</description><pubDate>Thu, 19 Nov 2026 18:30:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Neflamapimod Phase 2a Data in Primary Progressive Aphasia Show Exposure-Linked NfL Decline]]&gt;</title><link>https://www.neurologylive.com/view/neflamapimod-phase-2a-data-primary-progressive-aphasia-show-exposure-linked-nfl-decline</link><guid isPermaLink="true">https://www.neurologylive.com/view/neflamapimod-phase-2a-data-primary-progressive-aphasia-show-exposure-linked-nfl-decline</guid><description>&lt;![CDATA[In a phase 2a trial presented at CTAD 2026, neflamapimod kept plasma NfL stable in nonfluent variant primary progressive aphasia over 24 weeks.]]&gt;</description><pubDate>Thu, 19 Nov 2026 18:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[ALS Prevention, Gene Therapy, and Newborn Screening at MDA 2027]]&gt;</title><link>https://www.neurologylive.com/view/als-prevention-gene-therapy-and-newborn-screening-at-mda-2027</link><guid isPermaLink="true">https://www.neurologylive.com/view/als-prevention-gene-therapy-and-newborn-screening-at-mda-2027</guid><description>&lt;![CDATA[Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association (MDA), discussed the sessions he is most excited about at the 2027 MDA Clinical and Scientific Conference.]]&gt;</description><pubDate>Thu, 19 Nov 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Approves Venglustat as First Therapy for Neurological Manifestations of Type 3 Gaucher Disease]]&gt;</title><link>https://www.neurologylive.com/view/fda-approves-venglustat-first-therapy-neurological-manifestations-type-3-gaucher-disease</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-approves-venglustat-first-therapy-neurological-manifestations-type-3-gaucher-disease</guid><description>&lt;![CDATA[The FDA approved oral venglustat for neurological manifestations of type 3 Gaucher disease after the phase 3 LEAP2MONO trial showed superiority over imiglucerase on a combined ataxia and cognition measure.]]&gt;</description><pubDate>Thu, 19 Nov 2026 15:05:27 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Defining Treatment Success in MG]]&gt;</title><link>https://www.neurologylive.com/view/defining-treatment-success-in-mg</link><guid isPermaLink="true">https://www.neurologylive.com/view/defining-treatment-success-in-mg</guid><description>&lt;![CDATA[Successful MG treatment begins with defining what improvement means to the patient and revisiting those goals as disease control evolves. Supported by Vor Bio Medical Affairs.]]&gt;</description><pubDate>Thu, 19 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Addressing Unmet Needs with Emerging MG Therapies]]&gt;</title><link>https://www.neurologylive.com/view/addressing-unmet-needs-with-emerging-mg-therapies</link><guid isPermaLink="true">https://www.neurologylive.com/view/addressing-unmet-needs-with-emerging-mg-therapies</guid><description>&lt;![CDATA[The next generation of MG treatment may depend on combining rapid symptom control with upstream strategies designed to produce deeper and more sustained immune effects. Supported by Vor Bio Medical Affairs.]]&gt;</description><pubDate>Thu, 19 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Phase 2 SPINOZA Trial to Test CETP Inhibitor Obicetrapib in APOE-Stratified Preclinical Alzheimer Disease]]&gt;</title><link>https://www.neurologylive.com/view/phase-2-spinoza-trial-test-cetp-inhibitor-obicetrapib-apoe-stratified-preclinical-alzheimers</link><guid isPermaLink="true">https://www.neurologylive.com/view/phase-2-spinoza-trial-test-cetp-inhibitor-obicetrapib-apoe-stratified-preclinical-alzheimers</guid><description>&lt;![CDATA[A new phase 2b trial, SPINOZA, will test whether obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, slows Alzheimer disease biomarker progression in APOE-stratified, cognitively unimpaired adults.]]&gt;</description><pubDate>Thu, 19 Nov 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Approves Cemdisiran as New Treatment for Generalized Myasthenia Gravis]]&gt;</title><link>https://www.neurologylive.com/view/fda-approves-cemdisiran-as-new-treatment-generalized-myasthenia-gravis</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-approves-cemdisiran-as-new-treatment-generalized-myasthenia-gravis</guid><description>&lt;![CDATA[Cemdisiran (Livsayis), Regeneron’s complement C5-directed siRNA dosed four times a year, can now treat adults in the US who have AChR-antibody-positive generalized myasthenia gravis.]]&gt;</description><pubDate>Wed, 18 Nov 2026 23:16:47 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Perfuze Receives FDA Clearance for NeuroSheath 8F Long Sheath]]&gt;</title><link>https://www.neurologylive.com/view/perfuze-receives-fda-clearance-neurosheath-8f-long-sheath</link><guid isPermaLink="true">https://www.neurologylive.com/view/perfuze-receives-fda-clearance-neurosheath-8f-long-sheath</guid><description>&lt;![CDATA[FDA 510(k) clearance adds an 8F neurovascular access sheath to Perfuze’s portfolio, designed to accommodate aspiration catheters up to 0.088 inches, including Millipede88.]]&gt;</description><pubDate>Wed, 18 Nov 2026 23:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Levetiracetam Misses Primary Endpoint in Early Alzheimer Trial]]&gt;</title><link>https://www.neurologylive.com/view/levetiracetam-misses-primary-endpoint-early-alzheimer-trial</link><guid isPermaLink="true">https://www.neurologylive.com/view/levetiracetam-misses-primary-endpoint-early-alzheimer-trial</guid><description>&lt;![CDATA[A phase 2a crossover trial testing low-dose and high-dose levetiracetam in early Alzheimer disease did not significantly improve global cognition versus placebo.]]&gt;</description><pubDate>Wed, 18 Nov 2026 20:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Infarct Size Alone Doesn&apos;t Predict Thrombectomy Outcomes, Registry Shows]]&gt;</title><link>https://www.neurologylive.com/view/infarct-size-alone-predict-thrombectomy-outcomes-registry-shows</link><guid isPermaLink="true">https://www.neurologylive.com/view/infarct-size-alone-predict-thrombectomy-outcomes-registry-shows</guid><description>&lt;![CDATA[A real-world registry found that large infarct core size does not independently predict worse functional or safety outcomes after thrombectomy, compared with moderate-core infarcts.]]&gt;</description><pubDate>Wed, 18 Nov 2026 19:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Mevidalen Misses Primary Endpoint in Phase 2 Alzheimer Trial]]&gt;</title><link>https://www.neurologylive.com/view/mevidalen-misses-primary-endpoint-phase-2-alzheimer-trial</link><guid isPermaLink="true">https://www.neurologylive.com/view/mevidalen-misses-primary-endpoint-phase-2-alzheimer-trial</guid><description>&lt;![CDATA[Results from Eli Lilly&apos;s phase 2 PRESENCE-ALZ trial show the dopamine D1 receptor modulator missed its primary cognitive and functional goal in Alzheimer disease.]]&gt;</description><pubDate>Wed, 18 Nov 2026 16:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Beyond Relapses and MRI: Practical Ways to Monitor MS Control]]&gt;</title><link>https://www.neurologylive.com/view/beyond-relapses-and-mri-practical-ways-to-monitor-ms-control</link><guid isPermaLink="true">https://www.neurologylive.com/view/beyond-relapses-and-mri-practical-ways-to-monitor-ms-control</guid><description>&lt;![CDATA[No single measure captures whether MS is controlled. Brief, targeted questions and simple bedside maneuvers can detect subtle decline without lengthy assessments or a formal EDSS at every visit.]]&gt;</description><pubDate>Wed, 18 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Positioning B-Cell–Depleting Therapies in the MG Treatment Sequence]]&gt;</title><link>https://www.neurologylive.com/view/positioning-b-cell-depleting-therapies-in-the-mg-treatment-sequence</link><guid isPermaLink="true">https://www.neurologylive.com/view/positioning-b-cell-depleting-therapies-in-the-mg-treatment-sequence</guid><description>&lt;![CDATA[B-cell depletion moves treatment upstream but may require more time to achieve its full clinical effect. FcRn therapy can provide a potential bridge when faster disease control is needed.]]&gt;</description><pubDate>Wed, 18 Nov 2026 13:05:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[PIRA in MS: Recognizing Progression Independent of Relapse Activity]]&gt;</title><link>https://www.neurologylive.com/view/pira-in-ms-recognizing-progression-independent-of-relapse-activity</link><guid isPermaLink="true">https://www.neurologylive.com/view/pira-in-ms-recognizing-progression-independent-of-relapse-activity</guid><description>&lt;![CDATA[Progression independent of relapse activity persists even on highly effective therapy. It is a clinical phenomenon, and the patient&apos;s own account is often the earliest and most reliable signal.]]&gt;</description><pubDate>Wed, 18 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Switching Within or Across Drug Classes Safely in MG]]&gt;</title><link>https://www.neurologylive.com/view/switching-within-or-across-drug-classes-safely-in-mg</link><guid isPermaLink="true">https://www.neurologylive.com/view/switching-within-or-across-drug-classes-safely-in-mg</guid><description>&lt;![CDATA[Once a change in therapy is needed, the next question is whether to stay within the FcRn class or change mechanisms. Transition strategy matters because loss of disease control during a prolonged washout can carry meaningful clinical risk.]]&gt;</description><pubDate>Wed, 18 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Orlando Forum Weighs Dual Antiplatelet Therapy Duration After Stroke]]&gt;</title><link>https://www.neurologylive.com/view/orlando-forum-weighs-dual-antiplatelet-therapy-duration-after-stroke</link><guid isPermaLink="true">https://www.neurologylive.com/view/orlando-forum-weighs-dual-antiplatelet-therapy-duration-after-stroke</guid><description>&lt;![CDATA[At an HCPLive and NeurologyLive Clinical Forum in Orlando, David Z. Rose, MD, of USF Morsani College of Medicine, discussed residual recurrence risk, dual antiplatelet therapy duration, and factor XIa inhibition in noncardioembolic stroke.]]&gt;</description><pubDate>Wed, 18 Nov 2026 13:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[NeuroVoices: Brian Lin, PhD, on the FDA Approval of Gefurulimab for Generalized Myasthenia Gravis]]&gt;</title><link>https://www.neurologylive.com/view/neurovoices-brian-lin-fda-approval-gefurulimab-generalized-mg</link><guid isPermaLink="true">https://www.neurologylive.com/view/neurovoices-brian-lin-fda-approval-gefurulimab-generalized-mg</guid><description>&lt;![CDATA[The senior director of research at the Muscular Dystrophy Association discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.]]&gt;</description><pubDate>Wed, 18 Nov 2026 11:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[AR1001 Slows Decline in Monotherapy Group of Phase 3 Alzheimer Trial]]&gt;</title><link>https://www.neurologylive.com/view/ar1001-slows-decline-monotherapy-group-phase-3-alzheimer-trial</link><guid isPermaLink="true">https://www.neurologylive.com/view/ar1001-slows-decline-monotherapy-group-phase-3-alzheimer-trial</guid><description>&lt;![CDATA[Phase 3 POLARIS-AD results show AR1001 benefit on CDR-SB in a prespecified monotherapy population, but not in the overall early Alzheimer disease population.]]&gt;</description><pubDate>Tue, 17 Nov 2026 22:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C]]&gt;</title><link>https://www.neurologylive.com/view/fda-approves-adrabetadex-first-therapy-improve-survival-infantile-onset-niemann-pick-disease-type-c</link><guid isPermaLink="true">https://www.neurologylive.com/view/fda-approves-adrabetadex-first-therapy-improve-survival-infantile-onset-niemann-pick-disease-type-c</guid><description>&lt;![CDATA[The FDA approved Beren Therapeutics&apos; adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.]]&gt;</description><pubDate>Tue, 17 Nov 2026 20:08:33 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Full X-TOLE2 Data Detail Azetukalner&apos;s Dose-Dependent Profile in Focal Epilepsy]]&gt;</title><link>https://www.neurologylive.com/view/full-x-tole2-data-detail-azetukalner-dose-dependent-profile-focal-epilepsy</link><guid isPermaLink="true">https://www.neurologylive.com/view/full-x-tole2-data-detail-azetukalner-dose-dependent-profile-focal-epilepsy</guid><description>&lt;![CDATA[Peer-reviewed results from the phase 3 X-TOLE2 trial, published in JAMA Neurology, detail azetukalner&apos;s seizure reduction and dose-dependent adverse events in adults with focal epilepsy.]]&gt;</description><pubDate>Tue, 17 Nov 2026 20:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item><item><title>&lt;![CDATA[Spectris Misses Primary End Point in Pivotal HOPE Trial for Alzheimer Disease]]&gt;</title><link>https://www.neurologylive.com/view/spectris-misses-primary-end-point-pivotal-hope-trial-alzheimer-disease</link><guid isPermaLink="true">https://www.neurologylive.com/view/spectris-misses-primary-end-point-pivotal-hope-trial-alzheimer-disease</guid><description>&lt;![CDATA[In the prespecified mild subgroup of HOPE, 40-Hz gamma sensory stimulation was associated with 56% slowing on the ADCS-ADL and 47% slowing on the CDR-SB vs sham at 12 months.]]&gt;</description><pubDate>Tue, 17 Nov 2026 18:00:00 GMT</pubDate><media:credit role="publishing company">NeurologyLive - Clinical Neurology News and Neurology Expert Insights</media:credit><category>us</category><source url="https://www.neurologylive.com/rss.xml">NeurologyLive - Clinical Neurology News and Neurology Expert Insights Articles</source></item></channel></rss>